623 related articles for article (PubMed ID: 14561707)
1. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR.
Zhang H; Cicchetti G; Onda H; Koon HB; Asrican K; Bajraszewski N; Vazquez F; Carpenter CL; Kwiatkowski DJ
J Clin Invest; 2003 Oct; 112(8):1223-33. PubMed ID: 14561707
[TBL] [Abstract][Full Text] [Related]
2. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.
Zhang H; Bajraszewski N; Wu E; Wang H; Moseman AP; Dabora SL; Griffin JD; Kwiatkowski DJ
J Clin Invest; 2007 Mar; 117(3):730-8. PubMed ID: 17290308
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
[TBL] [Abstract][Full Text] [Related]
4. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.
Shah OJ; Wang Z; Hunter T
Curr Biol; 2004 Sep; 14(18):1650-6. PubMed ID: 15380067
[TBL] [Abstract][Full Text] [Related]
5. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
6. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
Kwiatkowski DJ
Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
8. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex.
Brugarolas J; Lei K; Hurley RL; Manning BD; Reiling JH; Hafen E; Witters LA; Ellisen LW; Kaelin WG
Genes Dev; 2004 Dec; 18(23):2893-904. PubMed ID: 15545625
[TBL] [Abstract][Full Text] [Related]
9. Cell size regulation by the human TSC tumor suppressor proteins depends on PI3K and FKBP38.
Rosner M; Hofer K; Kubista M; Hengstschläger M
Oncogene; 2003 Jul; 22(31):4786-98. PubMed ID: 12894220
[TBL] [Abstract][Full Text] [Related]
10. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling.
Inoki K; Li Y; Zhu T; Wu J; Guan KL
Nat Cell Biol; 2002 Sep; 4(9):648-57. PubMed ID: 12172553
[TBL] [Abstract][Full Text] [Related]
11. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Roux PP; Ballif BA; Anjum R; Gygi SP; Blenis J
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13489-94. PubMed ID: 15342917
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin.
Tee AR; Anjum R; Blenis J
J Biol Chem; 2003 Sep; 278(39):37288-96. PubMed ID: 12867426
[TBL] [Abstract][Full Text] [Related]
13. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.
Mourani PM; Garl PJ; Wenzlau JM; Carpenter TC; Stenmark KR; Weiser-Evans MC
Circulation; 2004 Mar; 109(10):1299-306. PubMed ID: 14993145
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation.
Chan JA; Zhang H; Roberts PS; Jozwiak S; Wieslawa G; Lewin-Kowalik J; Kotulska K; Kwiatkowski DJ
J Neuropathol Exp Neurol; 2004 Dec; 63(12):1236-42. PubMed ID: 15624760
[TBL] [Abstract][Full Text] [Related]
15. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
16. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
17. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.
Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N
J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121
[TBL] [Abstract][Full Text] [Related]
18. Serine 302 Phosphorylation of Mouse Insulin Receptor Substrate 1 (IRS1) Is Dispensable for Normal Insulin Signaling and Feedback Regulation by Hepatic S6 Kinase.
Copps KD; Hançer NJ; Qiu W; White MF
J Biol Chem; 2016 Apr; 291(16):8602-17. PubMed ID: 26846849
[TBL] [Abstract][Full Text] [Related]
19. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
20. A complex interplay between Akt, TSC2 and the two mTOR complexes.
Huang J; Manning BD
Biochem Soc Trans; 2009 Feb; 37(Pt 1):217-22. PubMed ID: 19143635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]